加载中
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
收盘时
US$9.78
−US$0.16 · -1.61%
盘后
US$9.8414
+US$0.0614 · +0.63%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
日内区间
当前US$9.78
52周区间
当前US$9.78
盘中时间采用ET。市场数据可能有所延迟。
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
日内区间
当前US$9.78
52周区间
当前US$9.78
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | — | 12.5万 USD | 12.5万 USD |
| 毛利 | — | — | — | 12.5万 USD | 12.5万 USD |
| 研究与开发 | 3049.6万 USD | 1931.4万 USD | 2450.6万 USD | 2078.7万 USD | 1517.8万 USD |
| 销售、一般及管理费用 | 1777万 USD | 1405.7万 USD | 1388.5万 USD | 1406万 USD | 1067.3万 USD |
| 营业费用 | 4826.6万 USD | 3337.1万 USD | 3839.1万 USD | 3479.9万 USD | 2585.1万 USD |
| 利息收入 | 391.5万 USD | 108.6万 USD | 208.1万 USD | 121.8万 USD | — |
| 利息支出 | 211.9万 USD | 209万 USD | 259.5万 USD | 170.8万 USD | — |
| 折旧和摊销 | 84.5万 USD | 99万 USD | 96万 USD | 77.8万 USD | 23.2万 USD |
| 营业利润 | −4826.6万 USD | −3337.1万 USD | −3839.1万 USD | −3467.4万 USD | −2572.6万 USD |
| 净利润 | −3818.2万 USD | −5517.7万 USD | −3793.9万 USD | −1879.4万 USD | −3612.4万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$22.50
上涨空间 130.06%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2572.22万0.00%2.3万亿 USD0.03%US$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI2133万0.22%98.74亿 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM1663.21万0.02%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF871.64万0.01%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO538.07万0.04%139.17亿 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO476.51万0.03%180亿 USD0.06%US$112.27-0.35%
iShares Biotechnology ETFIBB467.11万0.04%108.2亿 USD0.44%US$204.26-1.08%
Schwab U.S. Small-Cap ETFSCHA374.23万0.02%218.24亿 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
